Efficacy of Viable Cartilage Allograft in talar osteochondral lesions

Osteochondral lesion of the talus are common and can be present in upto 6.5% of the population. While some may be asymptomatic, others can cause pain affecting lifestyle and potential lead to accelerated wear and potential arthritis. Traditionally microfracture has been the mainstay of surgical treatment however this can be associated with ongoing symptoms. The purpose of this pilot study is to assess the clinical efficacy of viable cartilage allograft in treating talar osteochondral lesions. Patients enrolled in the study will receive Viable cartilage allograft. The viable cartilage allograft (CartiMax) is supplied by CONMED corporation. As part of the procedure, an ankle arthroscopy will be performed in an operating theatre of a an Australian hospital. The lesion will be identified, prepared and the viable cartilage allograft will then be inserted. The surgery will take approximately 60 minutes. The surgeons involved are Australian trained foot and ankle orthopaedic surgeons with a number of years of experience. The surgeon performing the surgery will be implanting the allograft.